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a  b  s  t  r  a  c  t
Primary osteogenic sarcoma of the breast is a rare neoplasm, diagnosed mainly by patho-
histological and immunohistochemical analysis.
We  hereby present a case of primary osteogenic sarcoma in the right breast of a 62-year-
old  woman with synchronous appearance of an invasive ductal carcinoma. Clinical findings
are manifested with two separate painless formations 2.5 cm/2 cm and 1.5 cm/1 cm in size,
located on the border of the upper and lower lateral quadrant of the right breast. No axil-
lary lymphadenopathy was diagnosed. The pathohistological and immunohistochemistry
findings of both tumors revealed a synchronous manifestation of two  distinct neoplasms
–  epithelial and non-epithelial. Multimodality treatment consisted of Patey’s radical mas-
tectomy; 3 cycles of adjuvant chemotherapy; postoperative 50 Gy radiotherapy to the chest
wall  followed by additional 3 cycles of chemotherapy and anti-estrogen hormonotherapy.
Due  to the rarity of osteogenic mammary sarcoma, even more so in a combination with
epithelial breast tumors, its clinical features are unclear and optimal treatment remainscontroversial. Considering the poor prognosis of the combination of both malignomas, we
discuss a number of diagnostic and therapeutic issues.
© 2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All1.  BackgroundExtraskeletal osteosarcoma is a rare malignancy that accounts
for <1% of all soft-tissue sarcomas. Primary osteogenic
sarcoma of the breast occurs in 2–4% of all osteosarcomas1
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and in 0.1% of primary neoplasms of the breast.2,3 Extraskele-
tal sarcoma of the breast is considered an aggressive
disease with early local recurrence and distant hematogenic
metastases.3–8
We  present a casuistic clinical case of a synchronous
occurrence of mammary  osteosarcoma and invasive ductal
carcinoma, localized in one breast.
Urban & Partner Sp. z o.o. All rights reserved.
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Fig. 2 – Mammographic features of both lesions in the right
breast. (A) 1 – osteosarcoma and 2 – carcinoma..  Case  presentation
ixty-two-year-old Caucasian woman has developed an
symptomatic two lumps in the right breast. We  have to
ention, that 6 months before a regular prophylactic mam-
ography was negative (Fig. 1 ).
Two tumor lesions were visualized on mammography at
he border of both superior outer and inferior outer quadrants
f the right breast (Figs. 2 and 3).
Detailed mammographic description:  Two lesions were seen
gainst the background of profound fat regression: (1) High
ensity lesion 42/30 mm in size with unclear lobular contours
nd eccentric intra-lesion calcificates. (2) Spicular 20/19 mm
ump with defined irregular contours (Fig. 2).
Detailed sonography description of the right breast:  First lesion
as an irregular lobular contour. Second lesion has also lobular
Fig. 3 – Diagnostic sonograpcontour with decrease of US signal in its distal part. Additional
founding – enlarged right axillary lymph nodes (Fig. 3).
Staging CT scan and skeletal scintigraphy showed no evi-
dence of metastatic disease.
3.  Multimodality  treatment
The patient was treated with a radical Patey’s mastectomy.
Detailed pathohistological and imunohistochemical analy-
sis revealed two different malignomas – a rare extraskeletal
osteosarcoma synchronous (Fig. 4); with an invasive epithelial
invasive ductal cancer (Fig. 5).
Three courses of adjuvant chemotherapy with Pharmaru-
bicin and Endoxan were followed by 50 Gy postoperative
hy of the right breast.
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Fig. 4 – Photomicrograph showing: primary mammary
osteosarcoma of the right breast Hematoxylin and Eosin
stain (H&E) 40×.
Fig. 5 – Photomicrograph showing: invasive
moderately-differentiated ductal carcinoma of the right
breast. Hematoxylin and Eosin stain (H&E) 40×.
Fig. 6 – IHC picture of CKAE1/AE3 positive metastasis of
invasive ductal carcinoma in only one of axillary lymph
nodes of the right breast.radiotherapy to the chest wall and additional 3 courses of same
regime chemotherapy. Finally, she was put on Letrozole.
4.  Pathohistological  findings  of  both
tumors
Macroscopical description revealed a part of the mammary  gland
to show two separate tumor lesions, found at a distances of
5 cm from each other, without skin engagement and with free
resection lines. The first tumor was 1.5 cm/1 cm in size; whitish-
yellow in color. The second tumor was 2.5 cm/2 cm in size with
thick cut surface. Among the axillary adipose tissue, 11 axillary
lymph nodes were dissected.Classical microscopic description shows an infiltration by
elongated and oval multinucleated and monstrous cells sur-
rounded by neoplastic osteoid matter; with increased mitotic
activity 50 mitoses/10 HPF; and presence of hemorrhages(Fig. 4). On immunohistochemistry (IHC) tumor cells were
Vimentin positive, Ki67 was elevated up to 50%; epithe-
lial markers CK AE1/AE3 and CK7 were negative, as well
as estrogen, progesterone receptors and HER2 oncoprotein.
The diagnosis was extraskeletal osteosarcoma of the right
breast.
The second lumps looks different – in the moderate amount
of fibrovascular stroma a proliferation of tubular structures
and tumor cell groups with abundant eosinophilic cytoplasm,
pleomorphic nuclei and prominent nucleons were seen; cells
mitotic activity was moderate 30 mitoses/10 HPF (Fig. 5). On
immunohistochemistry (IHC) neoplastic cells were positive
for CK7, CKAE1/AE3, ER, PR; HER2 oncoprotein was nega-
tive and Ki-67 was 20%. Histological diagnosis was invasive
moderately-differentiated ductal carcinoma of the right breast
– pT2N1G2.
Microscopic description of dissected right axillary lymph nodes:
Among the 11 dissected lymph nodes, only one had ductal car-
cinoma metastases. IHC confirmed the epithelial origin of it:
Vimentin (−); ER-(+); Cytokeratins (CK) – CK AE1/AE3(+) (Fig. 6).
5.  Follow  up
The left breast sonography and mammography did not show
any suspected focal lesions.
Laboratory findings were normal, including the preoper-
ative alkaline phosphatase and tumor marker CA 15-3 was
normal/les 30 U/ml serum level.
Post-treatment follow up mammography of the left breast: The
residual fibroglandular elements showed mastopatic changes
of fibrotic type without suspected solid or cystic distortions. A
single benign view classification. No axillary adenopathy. Skin
and subskin tissues looked normal (Fig. 7A and B).
CT scan and skeletal scintigraphy after 2 years showed no
evidence of metastatic disease.Two years after treatment the patient is disease free and
continues her treatment with Letrozole.
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ue to the rare occurrence of primary osteosarcoma of the
reast, the oncologist faces a number of diagnostic and
herapeutic issues. Pathohistological diagnosis of osteogenic
arcoma of soft tissues requires a combination of three main
lements: (1) presence of neoplastic osteoid or bone formation
ithin the tumor cells; (2) exclusion of primary bone neoplasm
nd (3) absence of malignant epithelial components in the
umor cells.9 In our case the pathohistological and immuno-
istochemical analysis of the first neoplastic lump proved the
resence of a neoplastic osteoid as well as absence of Cytoker-
tins (CK AE1/AE3 (−) and CK7 (−)), evidencing non-epithelial
haracter of the tumor.1–3,17 The presence of bone formation
r osteoid element in epithelial invasive ductal and lobular
eoplasia is rare. It is defined as metaplastic carcinoma, char-
cterized by metaplastic epithelial neoplasia after IHC positive
o Cytokeratins.10
This clinical case with two distinct neoplasms with
pithelial and non-epithelial characteristics occurring syn-
hronously makes the prognosis, which determines adequate
ostoperative adjuvant therapy, difficult. Primary osteosar-
oma of the breast is a biologically aggressive tumor
haracterized by early local recurrence (43% in the first year)
nd hematogenous metastases – to the lungs, bone, liver and
oft tissue (cutaneous and subcutaneous). The incidence rates
f this soft-tissue sarcoma resembles the primary osteosar-
oma with a low 5-year overall survival rate – approximately
8%.3,11–13 Literature reports factors defined as significantly
orsening the prognosis – tumor size, histological subtype
osteoclastic variant), resection margins pathohistologically
ositive to tumor cells, number of mitoses and presence of
istant metastases.12,13 In this tumor synchronicity, the prog-
osis is significantly worsened, despite the initial clinical
tage of each neoplasm (epithelial and non-epithelial). The
umulative number of adverse factors of the invasive ductal
arcinoma (G2, pT2 N1) on the one hand, and of the osteosar-
oma of the breast/G3; Кi 67-positive in 50%/, on the other
14,15and, predefine the worsened individual prognosis.
Optimal treatment of osteosarcoma of the breast involve
adical surgery (wide local margin of resection with clean
esection margins), such as Patey’s radical mastectomy in ourcase.3,6 Adjuvant radiotherapy of the chest wall scar signifi-
cantly improves local tumor control (LTC) – minimizes local
recurrence.16 Despite the presence of two small-size neo-
plasias, epithelial 2.5 cm/2 cm in diameter and non-epithelial
1.5 cm/1 cm in diameter, and the radical surgery, Patey’s mas-
tectomy, given the local aggressiveness of osteosarcoma, we
conducted a postoperative radiotherapy of the entire chest
wall. As is the case with the other types of soft-tissue
extraskeletal sarcomas, in 50% of the cases, hematogenous
metastases develop, rarely lymphatic – in the nearest lymph
nodes. The progression of the disease leads to exitus letalis
in 2–10 months.3,6,11–13 The presence of lymphatic metastases
requires cisplatin/ifosfamide-based chemotherapy, which sig-
nificantly improves the long-term survival rate.6,16 In the case
presented here–synchronous occurrence of invasive ductal
carcinoma рT2N1М0 and osteosarcoma of the breast with-
out lymphatic metastases, the chemotherapy is used because
of the рN1 of the invasive breast cancer.
7.  Conclusion
Primary osteosarcoma of the breast is a rare neoplasm. Syn-
chronous unilateral occurrence of invasive carcinoma of the
breast and osteogenic sarcoma of the breast is casuistry.
This clinical case is presented to focus on the significance of
pathohistological and immunohistochemical analysis in the
differential diagnosis between epithelial and non-epithelial
mammary  neoplasm. The optimal complex treatment is, on
the one hand, based on an accurate assessment of all factors
of invasive carcinoma, and on the other hand, on extraskeletal
mesenchymal tumor that worsens the prognosis. In the case
presented here, we  reported 2-year free survival (without local
recurrence and distant metastases).
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